Examples of using Xiapex in English and their translations into Greek
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Financial
-
Official/political
-
Computer
For Peyronie's disease, Xiapex was compared with placebo in two further studies involving 832 men.
The company that markets Xiapex must also ensure that all doctors expected to use the medicine are.
Your doctor must not use Xiapex if the reconstituted solution is discoloured
Xiapex must be reconstituted with the solvent provided
Severe allergic reactions can happen in patients who receive Xiapex, because it contains proteins foreign to the human body.
higher titers with successive Xiapex injections.
After treatment with Xiapex, one of these tubes may break during an erection.
Xiapex has not been studied in children
Xiapex was not associated with shortening of penile length in clinical trials in the treatment of Peyronie's disease.
The vial containing Xiapex and the vial containing the solvent for solution for injection for reconstitution must be refrigerated.
Since the enzymes in Xiapex have some sequence homology with human matrix metalloproteinases(MMPs),
Data on the long-term recurrence rates following successful treatment with Xiapex are provided in Table 7.
Whilst there is no clinical evidence from the current safety data of a musculoskeletal syndrome developing following the administration of Xiapex, the potential for it to occur cannot be excluded.
On this plan, safety information has been included in the summary of product characteristics and the package leaflet for Xiapex, including the appropriate precautions to be followed by healthcare.
was not evaluated and 1 joint from the Xiapex treated group had a baseline contracture of 0 degrees before treatment).
The company that markets Xiapex must also ensure that all doctors expected to use the medicine are properly trained on the use of the medicine
All p-values< 0.001 for all comparisons between Xiapex and placebo, except for PIP joints in Study CORD II which was not eligible for statistical testing due to a hierarchical testing procedure.
Parturition or postnatal development studies in animals were not conducted since human pharmacokinetic studies show that Xiapex levels are not quantifiable in the systemic circulation following injection into a Dupuytren's cord(see section 5.1).
Care should be taken when injecting Xiapex into cords contracting the PIP joints as clinical studies indicate an increased risk of tendon rupture
Corporal rupture was reported as a serious adverse reaction after Xiapex injection in 5 out of 1044 patients(0.5%)